BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2857060)

  • 1. Prenalterol in symptomatic sinus node dysfunction.
    Feleke E; Rydén L; Smedgård P; Westerling S
    Am Heart J; 1985 Jan; 109(1):185-7. PubMed ID: 2857060
    [No Abstract]   [Full Text] [Related]  

  • 2. [Beta-adrenergic stimulation with prenalterol in sick sinus syndrome].
    Treese N; Russ M; Kasper W; Meinertz T; Pop T
    Z Kardiol; 1983 Aug; 72(8):481-6. PubMed ID: 6624189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short and long-term effects of hydralazine and combined hydralazine and prenalterol therapy in patients with congestive heart failure.
    Drexler H; Löllgen H; Just H
    Acta Med Scand Suppl; 1982; 659():315-24. PubMed ID: 6127898
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolic effects of prenalterol in diabetic patients.
    Oltmanns D
    Acta Med Scand Suppl; 1982; 659():147-55. PubMed ID: 6127885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the vasodilator prazosin and the selective beta1 agonist prenalterol on rest and exercise haemodynamics in CHF.
    Hutton I; Tweddel AC; Bastian BC; Murray RG
    Acta Med Scand Suppl; 1981; 652():163-8. PubMed ID: 6120615
    [No Abstract]   [Full Text] [Related]  

  • 6. Prenalterol as an antidote to massive doses of metoprolol--a cardiovascular study in the dog.
    Andersson T; Heath A; Mattsson H
    Acta Med Scand Suppl; 1982; 659():71-88. PubMed ID: 6127900
    [No Abstract]   [Full Text] [Related]  

  • 7. Echocardiographic comparison between prenalterol and dobutamine.
    Wester HA; Oltmanns D
    Acta Med Scand Suppl; 1982; 659():181-90. PubMed ID: 6127888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenalterol in the treatment of congestive heart failure developing during beta-blocking therapy. A comparison with frusemide in patients with acute myocardial infarction.
    Dahlström U; Karlsson E
    Acta Med Scand; 1982; 212(3):125-30. PubMed ID: 6128867
    [No Abstract]   [Full Text] [Related]  

  • 9. Hemodynamic effects of prenalterol in patients with ischemic heart disease and congestive cardiomyopathy.
    Erbel R; Meyer J; Lambertz H; Schweizer P; Voelker W; Krebs W; Braun G; Effert S
    Circulation; 1982 Aug; 66(2):361-9. PubMed ID: 6124326
    [No Abstract]   [Full Text] [Related]  

  • 10. Electrophysiologic properties of prenalterol.
    Capucci A; Frabetti L; Melandri G; Magnani B
    Int J Cardiol; 1983; 2(3-4):391-400. PubMed ID: 6132888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous prenalterol in acute and chronic heart failure.
    Kirlin PC; Pitt B; Lucchesi BR
    Acta Med Scand Suppl; 1982; 659():263-86. PubMed ID: 6127894
    [No Abstract]   [Full Text] [Related]  

  • 12. The hemodynamic actions of prenalterol in left ventricular failure.
    Awan NA; Evenson MK; Needham KE; Mason DT
    Acta Med Scand Suppl; 1982; 659():251-61. PubMed ID: 6127893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of prenalterol administered orally in patients with congestive heart failure.
    Hjalmarson A; Abelardo N; Caidahl K; Reyes C; Waagstein F; Wallentin I; Wikstrand J; Estrada-Yamamoto M
    Acta Med Scand Suppl; 1982; 659():201-20. PubMed ID: 6127890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo.
    Glover DR; Wathen CG; Murray RG; Petch MC; Muir AL; Littler WA
    Br Heart J; 1985 Feb; 53(2):208-15. PubMed ID: 2857088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulatory response to prenalterol in normal subjects and in patients with primary congestive cardiomyopathy.
    Guazzi MD; Qing LG; Olivari MT; Fiorentini C; Loaldi A; Bartorelli A; Moruzzi P; Polese A
    Acta Med Scand Suppl; 1982; 659():233-50. PubMed ID: 6127892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemodynamic effects of intravenously administered prenalterol in patients with severe heart failure.
    Waagstein F; Estrada-Yamamoto M; Reiz S; Reyes C; Hjalmarson A
    Acta Med Scand Suppl; 1982; 659():221-31. PubMed ID: 6127891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure.
    Rönn O
    Acta Med Scand Suppl; 1982; 659():89-98. PubMed ID: 6127901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compartment model of prenalterol.
    Klein G; Wirtzfeld A; Bozler G; Rönn O; Graffner C
    Acta Med Scand Suppl; 1982; 659():99-107. PubMed ID: 6127903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Circulatory effects of prenalterol (a selective beta-1 agonist) in normal subjects and in patients with primary congestive cardiomyopathy].
    Moruzzi P; Cipolla CM; Bartorelli A; Reggiani P; Ging LQ; Guazzi M
    Cardiologia; 1982; 27(1):99-101. PubMed ID: 6152733
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effects of Prenalterol on left ventricular function of coronary patients].
    Javernaro A; Bolognesi R; Giacometti P; Potenza D; Cortesi G; Cucchini F
    Acta Biomed Ateneo Parmense; 1983; 54(1):17-8. PubMed ID: 6134412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.